Frank Meiss

15PUBLICATIONS
80CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEthical use of new technologyHaematological tumoursMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 23, 2026
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.

|Oct 22, 2026
Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg.

|Sep 08, 2026
Cancer survivorship in malignant melanoma.

|Nov 22, 2025
Real-world management of adjuvant systemic melanoma therapy: Multi-center survey of 51 DeCOG skin cancer centers.

Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling

|Jan 03, 2025
Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanoma.

Markus Reitmajer, Elisabeth Livingstone, Kai-Martin Thoms

|Dec 20, 2024
Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells.

Zhen Zhang, Marlene Langenbach, Sagar Sagar

Pageof 3

Frequent Collaborators

5 joint publications

Andrea Forschner

4 joint publications

David Rafei-Shamsabadi

4 joint publications

Melanie Boerries

3 joint publications

Markus Reitmajer